61. Cheng CJ, Bahal R, Babar IA et al (2015) MicroRNA silencing for cancer therapy targeted
to the tumor microenvironment. Nature 518:107–110. https://doi.org/10.1038/nature13905
62. Ma KX, Wang HJ, Li XR et al (2015) Long noncoding RNA MALAT1 associates with the
malignant status and poor prognosis in glioma. Tumor Biol 36:3355–3359. https://doi.org/10.
1007/s13277-014-2969-7
63. Beier D, Schulz JB, Beier CP (2011) Chemoresistance of glioblastoma cancer stem cells –
much more complex than expected. Mol Cancer 10:1–11. https://doi.org/10.1186/1476-459810-128
64. Li H, Yuan X, Yan D et al (2017) Long non-coding RNA MALAT1 decreases the sensitivity
of resistant glioblastoma cell lines to temozolomide. Cell Physiol Biochem 42:1192–1201.
https://doi.org/10.1159/000478917
65. Kim S-S, Harford JB, Moghe M et al (2017) Targeted nanocomplex carrying siRNA against
MALAT1 sensitizes glioblastoma to temozolomide. Nucleic Acids Res 46:1424–1440. https://
doi.org/10.1093/nar/gkx1221
66. Daniels TR, Delgado T, Helguera G, Penichet ML (2006) The transferrin receptor part II:
targeted delivery of therapeutic agents into cancer cells. Clin Immunol 121:159–176. https://
doi.org/10.1016/j.clim.2006.06.006
67. Kim S-S, Rait A, Kim E et al (2017) Encapsulation of temozolomide in a tumor-targeting
nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma. Cancer Lett 369:250–258. https://doi.org/10.1016/j.canlet.2015.08.022
68. Katsushima K, Natsume A, Ohka F et al (2016) Targeting the Notch-regulated
non-coding RNA TUG1 for glioma treatment. Nat Commun 7:1–14. https://doi.org/10.1038/
ncomms13616
69. Fan X, Khaki L, Zhu TS et al (2010) NOTCH pathway blockade depletes CD133-positive
glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells
28:5–16. https://doi.org/10.1002/stem.254
70. Trimarchi T, Bilal E, Ntziachristos P et al (2014) Genome-wide mapping and characterization
of notch-regulated long noncoding RNAs in acute leukemia. Cell 158:593–606. https://doi.
org/10.1016/j.cell.2014.05.049
71. Suvà ML, Rheinbay E, Gillespie SM et al (2014) Reconstructing and reprogramming the
tumor-propagating potential of glioblastoma stem-like cells. Cell 157:580–594. https://doi.
org/10.1016/j.cell.2014.02.030
72. Zhu TS, Costello MA, Talsma CE et al (2011) Endothelial cells create a stem cell niche in
glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells.
Cancer Res 71:6061–6072. https://doi.org/10.1158/0008-5472.CAN-10-4269
73. Miura Y, Takenaka T, Toh K et al (2013) Cyclic RGD-linked polymeric micelles for targeted
delivery of platinum anticancer drugs to glioblastoma through the blood-brain tumor barrier.
ACS Nano 7:8583–8592. https://doi.org/10.1021/nn402662d
74. Xu R, Shimizu F, Hovinga K et al (2016) Molecular and clinical effects of notch inhibition
in glioma patients: a phase 0/I trial. Clin Cancer Res 22:4786–4796. https://doi.org/10.1158/
1078-0432.CCR-16-0048
75. Yahyanejad S, King H, Iglesias VS et al (2016) NOTCH blockade combined with
radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma. Oncotarget
7:41251–41264. https://doi.org/10.18632/oncotarget.9275
76. Simó-Riudalbas L, Esteller M (2015) Targeting the histone orthography of cancer: drugs
for writers, erasers and readers. Br J Pharmacol 172:2716–2732. https://doi.org/10.1111/bph.
12844
77. Pérez-Salvia M, Esteller M (2017) Bromodomain inhibitors and cancer therapy: from
structures to applications. Epigenetics 12:323–339. https://doi.org/10.1080/15592294.2016.
1265710
78. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase
inhibitors. Nat Rev Drug Discov 5:769–784. https://doi.org/10.1038/nrd2133
79. Morera L, Lübbert M, Jung M (2016) Targeting histone methyltransferases and demethylases
in clinical trials for cancer therapy. Clin Epigenetics 8:16. https://doi.org/10.1186/s13148-0160223-4
424
D. Hanly et al.
to the tumor microenvironment. Nature 518:107–110. https://doi.org/10.1038/nature13905
62. Ma KX, Wang HJ, Li XR et al (2015) Long noncoding RNA MALAT1 associates with the
malignant status and poor prognosis in glioma. Tumor Biol 36:3355–3359. https://doi.org/10.
1007/s13277-014-2969-7
63. Beier D, Schulz JB, Beier CP (2011) Chemoresistance of glioblastoma cancer stem cells –
much more complex than expected. Mol Cancer 10:1–11. https://doi.org/10.1186/1476-459810-128
64. Li H, Yuan X, Yan D et al (2017) Long non-coding RNA MALAT1 decreases the sensitivity
of resistant glioblastoma cell lines to temozolomide. Cell Physiol Biochem 42:1192–1201.
https://doi.org/10.1159/000478917
65. Kim S-S, Harford JB, Moghe M et al (2017) Targeted nanocomplex carrying siRNA against
MALAT1 sensitizes glioblastoma to temozolomide. Nucleic Acids Res 46:1424–1440. https://
doi.org/10.1093/nar/gkx1221
66. Daniels TR, Delgado T, Helguera G, Penichet ML (2006) The transferrin receptor part II:
targeted delivery of therapeutic agents into cancer cells. Clin Immunol 121:159–176. https://
doi.org/10.1016/j.clim.2006.06.006
67. Kim S-S, Rait A, Kim E et al (2017) Encapsulation of temozolomide in a tumor-targeting
nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma. Cancer Lett 369:250–258. https://doi.org/10.1016/j.canlet.2015.08.022
68. Katsushima K, Natsume A, Ohka F et al (2016) Targeting the Notch-regulated
non-coding RNA TUG1 for glioma treatment. Nat Commun 7:1–14. https://doi.org/10.1038/
ncomms13616
69. Fan X, Khaki L, Zhu TS et al (2010) NOTCH pathway blockade depletes CD133-positive
glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells
28:5–16. https://doi.org/10.1002/stem.254
70. Trimarchi T, Bilal E, Ntziachristos P et al (2014) Genome-wide mapping and characterization
of notch-regulated long noncoding RNAs in acute leukemia. Cell 158:593–606. https://doi.
org/10.1016/j.cell.2014.05.049
71. Suvà ML, Rheinbay E, Gillespie SM et al (2014) Reconstructing and reprogramming the
tumor-propagating potential of glioblastoma stem-like cells. Cell 157:580–594. https://doi.
org/10.1016/j.cell.2014.02.030
72. Zhu TS, Costello MA, Talsma CE et al (2011) Endothelial cells create a stem cell niche in
glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells.
Cancer Res 71:6061–6072. https://doi.org/10.1158/0008-5472.CAN-10-4269
73. Miura Y, Takenaka T, Toh K et al (2013) Cyclic RGD-linked polymeric micelles for targeted
delivery of platinum anticancer drugs to glioblastoma through the blood-brain tumor barrier.
ACS Nano 7:8583–8592. https://doi.org/10.1021/nn402662d
74. Xu R, Shimizu F, Hovinga K et al (2016) Molecular and clinical effects of notch inhibition
in glioma patients: a phase 0/I trial. Clin Cancer Res 22:4786–4796. https://doi.org/10.1158/
1078-0432.CCR-16-0048
75. Yahyanejad S, King H, Iglesias VS et al (2016) NOTCH blockade combined with
radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma. Oncotarget
7:41251–41264. https://doi.org/10.18632/oncotarget.9275
76. Simó-Riudalbas L, Esteller M (2015) Targeting the histone orthography of cancer: drugs
for writers, erasers and readers. Br J Pharmacol 172:2716–2732. https://doi.org/10.1111/bph.
12844
77. Pérez-Salvia M, Esteller M (2017) Bromodomain inhibitors and cancer therapy: from
structures to applications. Epigenetics 12:323–339. https://doi.org/10.1080/15592294.2016.
1265710
78. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase
inhibitors. Nat Rev Drug Discov 5:769–784. https://doi.org/10.1038/nrd2133
79. Morera L, Lübbert M, Jung M (2016) Targeting histone methyltransferases and demethylases
in clinical trials for cancer therapy. Clin Epigenetics 8:16. https://doi.org/10.1186/s13148-0160223-4
424
D. Hanly et al.